Exagen Inc (XGN) Stock Price, Quote & News

Company Profile

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative o...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 760 560 1501

Website: www.exagen.com

Address:

1261 Liberty Way, Suite C, Vista, United States

Savior79 Jun. 12 at 3:16 PM

$XGN jumped in at $7 🚀🚀🚀🚨🚨🚨🚨🚨🚨🚨🚨🚨

0 · Reply

Savior79 Jun. 11 at 2:54 PM

$XGN good loading zone here 🚨🚨🚨🚨🚨🚨🚨🚀🚀🚀🚀🚀🚀

0 · Reply

SK_Trading_Substack Jun. 11 at 2:53 PM

$AKRO $XGN $GSHD $ORIC $LOMA Today's most likely to have a big week.

0 · Reply

Savior79 Jun. 6 at 8:59 PM

$XGN time to buy Let’s make money!

0 · Reply

JarvisFlow May. 15 at 3:36 PM

Cantor Fitzgerald has updated their rating for Exagen ( $XGN ) to Overweight with a price target of 7.

0 · Reply

Savior79 May. 13 at 8:49 PM

$XGN $5.37 was a great price to Load up! 🤗🤗🤗🤗

0 · Reply

JarvisFlow May. 13 at 2:06 PM

Canaccord Genuity has updated their rating for Exagen ( $XGN ) to Buy with a price target of 8.

0 · Reply

Armonica423 May. 10 at 9:28 PM

$XGN big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

_www_larval_com_ May. 8 at 3:57 PM

$XGN just slipped -3% lower to -9% (~1Mv) in the last few minutes, 05/16 options, follow for more volatility.

0 · Reply

OpenOutcrier May. 8 at 1:03 PM

$XGN (-14.9% pre) Exagen Inc (XGN) Prices 3.5M Share Offering at $5.25/sh https://ooc.bz/l/64050

0 · Reply

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

May 8, 2025, 8:30 AM EDT - 5 weeks ago

Exagen Inc. Prices Public Offering of Common Stock

May 7, 2025, 4:05 PM EDT - 5 weeks ago

Exagen Inc. Announces Proposed Public Offering of Common Stock

May 5, 2025, 4:51 PM EDT - 6 weeks ago

Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript

May 5, 2025, 8:00 AM EDT - 6 weeks ago

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

Apr 28, 2025, 9:00 AM EDT - 7 weeks ago

Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors

Apr 26, 2025, 3:31 AM EDT - 7 weeks ago

Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability

Apr 21, 2025, 4:05 PM EDT - 2 months ago

Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

Mar 11, 2025, 1:13 PM EDT - 3 months ago

Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 8:00 AM EDT - 3 months ago

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

Feb 25, 2025, 4:05 PM EST - 3 months ago

Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

Feb 4, 2025, 4:05 PM EST - 4 months ago

Exagen Inc. to Participate in Upcoming Investor Conferences

Jan 12, 2025, 12:00 PM EST - 5 months ago

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Dec 12, 2024, 9:00 AM EST - 6 months ago

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

Nov 14, 2024, 4:30 PM EST - 7 months ago

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Nov 12, 2024, 1:09 PM EST - 7 months ago

Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript

Oct 21, 2024, 4:05 PM EDT - 8 months ago

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

Sep 4, 2024, 4:05 PM EDT - 10 months ago

Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference

Aug 5, 2024, 10:49 AM EDT - 11 months ago

Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 9:00 AM EDT - 11 months ago

Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 1, 2024, 9:00 AM EDT - 11 months ago

Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

Jul 22, 2024, 9:00 AM EDT - 11 months ago

Exagen to Announce Second Quarter 2024 Results on August 5, 2024

Jun 10, 2024, 1:14 PM EDT - 1 year ago

Time to Play 5 Top-Ranked Stocks With Rising P/E?

AMC APDN HCAT YOU

May 13, 2024, 11:25 AM EDT - 1 year ago

Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript

May 13, 2024, 8:00 AM EDT - 1 year ago

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year

Apr 30, 2024, 4:05 PM EDT - 1 year ago

Exagen to Announce First Quarter 2024 Results on May 13, 2024

Apr 26, 2024, 8:30 AM EDT - 1 year ago

Exagen Inc. Announces Changes to the Board of Directors

Mar 18, 2024, 1:23 PM EDT - 1 year ago

Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 8:00 AM EDT - 1 year ago

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results

Mar 8, 2024, 9:00 AM EST - 1 year ago

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 7, 2024, 4:05 PM EST - 1 year ago

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

Jan 7, 2024, 12:00 PM EST - 1 year ago

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

Nov 20, 2023, 8:37 AM EST - 1 year ago

Exagen Inc. (XGN) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 4:05 PM EST - 1 year ago

Exagen Inc. Reports Strong Third Quarter 2023 Results

Nov 9, 2023, 4:05 PM EST - 1 year ago

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

Oct 30, 2023, 4:05 PM EDT - 1 year ago

Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023

Sep 28, 2023, 4:05 PM EDT - 1 year ago

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting

Sep 12, 2023, 4:05 PM EDT - 1 year ago

Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 7, 2023, 1:42 PM EDT - 2 years ago

Exagen Inc. (XGN) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 8:00 AM EDT - 2 years ago

Exagen Inc. Reports Strong Second Quarter 2023 Results

Jul 26, 2023, 4:05 PM EDT - 2 years ago

Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Jul 25, 2023, 4:05 PM EDT - 2 years ago

Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023

Jul 24, 2023, 4:05 PM EDT - 2 years ago

Exagen Inc. Appoints Paul Kim to Board of Directors

May 30, 2023, 9:00 AM EDT - 2 years ago

Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference

May 15, 2023, 10:23 PM EDT - 2 years ago

Exagen Inc. (XGN) Q1 2023 Earnings Call Transcript

May 15, 2023, 4:05 PM EDT - 2 years ago

Exagen Inc. Reports First Quarter 2023 Results

Mar 20, 2023, 7:53 PM EDT - 2 years ago

Exagen Inc. (XGN) Q4 2022 Earnings Call Transcript

Mar 20, 2023, 4:05 PM EDT - 2 years ago

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

Feb 27, 2023, 9:00 AM EST - 2 years ago

Exagen Inc. to Participate in Upcoming March Conferences

Jan 30, 2023, 4:05 PM EST - 2 years ago

Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Savior79 Jun. 12 at 3:16 PM

$XGN jumped in at $7 🚀🚀🚀🚨🚨🚨🚨🚨🚨🚨🚨🚨

0 · Reply

Savior79 Jun. 11 at 2:54 PM

$XGN good loading zone here 🚨🚨🚨🚨🚨🚨🚨🚀🚀🚀🚀🚀🚀

0 · Reply

SK_Trading_Substack Jun. 11 at 2:53 PM

$AKRO $XGN $GSHD $ORIC $LOMA Today's most likely to have a big week.

0 · Reply

Savior79 Jun. 6 at 8:59 PM

$XGN time to buy Let’s make money!

0 · Reply

JarvisFlow May. 15 at 3:36 PM

Cantor Fitzgerald has updated their rating for Exagen ( $XGN ) to Overweight with a price target of 7.

0 · Reply

Savior79 May. 13 at 8:49 PM

$XGN $5.37 was a great price to Load up! 🤗🤗🤗🤗

0 · Reply

JarvisFlow May. 13 at 2:06 PM

Canaccord Genuity has updated their rating for Exagen ( $XGN ) to Buy with a price target of 8.

0 · Reply

Armonica423 May. 10 at 9:28 PM

$XGN big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

_www_larval_com_ May. 8 at 3:57 PM

$XGN just slipped -3% lower to -9% (~1Mv) in the last few minutes, 05/16 options, follow for more volatility.

0 · Reply

OpenOutcrier May. 8 at 1:03 PM

$XGN (-14.9% pre) Exagen Inc (XGN) Prices 3.5M Share Offering at $5.25/sh https://ooc.bz/l/64050

0 · Reply

briefingcom May. 8 at 12:05 PM

Gapping down: $ERII -25.8% $DNUT -24.2% $XGN -19% $FLNC -15% $G -9.6%

0 · Reply

v92 May. 7 at 10:51 PM

$XGN Whelp. Rug pull. Guess just another biotech scam.

0 · Reply

DonCorleone77 May. 5 at 12:05 PM

$XGN Exagen sees FY25 revenue at least $65M, consensus $64.69M The company expects 2025 full-year revenue of at least $65 million and anticipates being on-track to deliver positive adjusted EBITDA in the fourth quarter of 2025.

0 · Reply

DonCorleone77 May. 5 at 12:04 PM

$XGN Exagen reports Q1 EPS (20c), consensus (21c) Reports Q1 revenue $15.498M, consensus $14.55M.

0 · Reply

_www_larval_com_ Apr. 30 at 7:57 PM

$SOGP -4%[-30%] $XGN -4%[-9%] most notable movement into the final minutes of trading.

0 · Reply

kiwitc2000 Apr. 29 at 11:06 PM

$TGTX $XGN $EHC Healthcare picks for rest of week. Strong as moonshine in the face of these strange times.

0 · Reply

v92 Apr. 29 at 6:46 PM

$XGN 😉

0 · Reply

_www_larval_com_ Apr. 29 at 1:53 PM

$XGN has stumbled -7% lower to -3% (~31Kv) a few minutes ago, 05/16 options, follow for more volatility.

0 · Reply

Savior79 Apr. 28 at 5:31 PM

$XGN this will not stop better get on board now!!!

0 · Reply

PenkeTrading Apr. 24 at 7:35 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Exagen Inc. Is that bullish or bearish? $XGN #Exagen #RsiOverbought #NASDAQ

0 · Reply

v92 Apr. 24 at 1:28 AM

$XGN Been an absolute hidden gem. Retail will eventually find this.

1 · Reply

v92 Apr. 23 at 8:06 PM

$XGN

0 · Reply

Market Cap	151.66M
Revenue (ttm)	55.64M
Net Income (ttm)	-15.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-27.17%
Debt to Equity Ratio	3.27

Volume	263,200
Avg Vol	239,300
Day's Range	N/A - N/A
Shares Out	21.30M
Stochastic %K	73%
Beta	1.60
Analysts	Strong Sell
Price Target	$7.75